Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cardiovascular diseases

Researchers suggest that beta blockers do not cut death risk after heart attack

Consensus is that a randomised controlled trial is needed to establish whether beta blockers should continue to be standard care for heart attack patients.

A large British study has cast doubt on the benefits of using beta blockers in patients after they have had acute myocardial infarction (MI), at least in those without heart failure. 

Researchers studied data from more than 179,000 patients and found no difference in death rates between those who were prescribed the drugs after a heart attack and those who were not. 

Historically, beta blockers have been the standard of care for patients with acute myocardial infarction, but this study suggests that UK guidelines to prescribe the drugs to all patients after heart attack — irrespective of whether or not they have heart failure — may need reconsideration. 

The researchers stress that this was only an observational study and that a randomised controlled trial would be needed to definitively assess which patients may not need to take the drugs. 

In the analysis, which took data from the Myocardial Ischaemia National Audit Project for England and Wales, there were 91,895 patients who had been hospitalised with ST-segment elevation myocardial infarction and 87,915 patients with non ST-segment elevation myocardial infarction. 

Most patients in both groups (96.4% and 93.2% respectively) received beta blockers, report the researchers who published their findings in the Journal of the American College of Cardiology[1] (online, 29 May 2017). 

Overall, there were 9,373 deaths and at first the calculations suggested a lower one-year mortality for patients who were given beta blockers. But after adjusting for several factors, the difference was found not to be significant for both types of heart attack. 

Study author Chris Gale, professor of cardiovascular medicine at the University of Leeds and consultant cardiologist at York Teaching Hospital Trust, said while the study did not carry sufficient weight to change practice, the findings along with other research suggest more work is needed. 

“Evidence for the effectiveness [of beta blockers] predates the modern management of heart attack, such as the advent of revascularisation and the other MI pharmacotherapies, and the historical trials included patients with heart failure or left ventricular dysfunction,” he said. 

He added that it was clear that patients with heart failure or left ventricular systolic dysfunction benefited from beta blockers. 

head shot Robert Henderson of the British  Cardiovascular Society

Source: Courtesy British Cardiovascular Society

Robert Henderson of the British Cardiovascular Society, says that trials showing benefits for beta blockers were done before the advent of newer treatments and that a randomised controlled trial is now needed.

Robert Henderson, honorary secretary of the British Cardiovascular Society, said giving everyone a beta blocker after a heart attack had become part of established medical practice but the trials that showed benefit were done before the advent of newer treatment options including primary angioplasty, which had dramatically altered the outcome for patients.

“They conclude we need a randomised controlled trial and I would agree with that. This paper is not going to change practice but it is a pointer towards the need for an RCT.” 

He added that while the researchers had done a sophisticated analysis there could be unknown variables that were never measured that could have influenced the outcome.

The British Heart Foundation estimates there are around 950,000 people in the UK who have survived a heart attack.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202874

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £47.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Introducing Palliative Care (IPC 5)

    Introducing Palliative Care (IPC 5)

    A key resource for students, covering the recommended palliative curriculum for medical undergraduates.

    £25.00Buy now
  • Health Economics

    Health Economics

    Health Economics is a practical analysis of the prominent economic issues facing the American health care system, and what mechanisms exist to counter it.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • head shot Robert Henderson of the British  Cardiovascular Society

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.